The healthcare professional (HCP) meeting landscape is evolving, but even as it adjusts to the demands of the digital age new research has shown that face-to-face meetings retain a prominent place
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh